X0306 4 2018-01-03 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001291959 Davis Robert E C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 SVP, Chief Scientific Officer Common Stock 2018-01-03 4 M 0 2648 A 30512 D Common Stock 2018-01-04 4 S 0 1115 15.60 D 29397 D Restricted Stock Units 2018-01-03 4 M 0 2648 0.00 D Common Stock 2648 5298 D Stock Option (right to buy) 15.47 2018-01-03 4 A 0 65164 0.00 A 2028-01-03 Common Stock 65164 65164 D Restricted Stock Units 2018-01-03 4 A 0 48480 0.00 A Common Stock 48480 48480 D Restricted stock units convert into common stock on a one-for-one basis. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock. On January 3, 2017, the reporting person was granted 7,946 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 3, 2018, the reporting person was granted options to purchase 65,164 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Lawrence J. Hineline, Attorney-in-fact 2018-01-05